Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Hepatitis C

  Free Subscription


Articles published in J Infect Dis

Retrieve available abstracts of 46 articles:
HTML format



Single Articles


    September 2021
  1. WARD KM, Falade-Nwulia O, Moon J, Sutcliffe CG, et al
    Non-adherence to LDV/SOF did not predict SVR in a randomized controlled trial of HIV/HCV coinfected persons who use drugs.
    J Infect Dis. 2021 Sep 20. pii: 6372878. doi: 10.1093.
    PubMed     Abstract available


    March 2021
  2. ARANDAY-CORTES E, McClure CP, Davis C, Irving WL, et al
    Real-World Outcomes of DAA Treatment and Retreatment in UK-based Patients Infected with HCV Genotypes/Subtypes Endemic in Africa.
    J Infect Dis. 2021 Mar 1. pii: 6154708. doi: 10.1093.
    PubMed     Abstract available


    February 2021
  3. CHUAYPEN N, Jinato T, Avihingsanon A, Chirapongsathorn S, et al
    Improvement of Gut Diversity and Composition after Direct-Acting Antivirals in HCV-Infected Patients with or without HIV Coinfection.
    J Infect Dis. 2021 Feb 17. pii: 6141513. doi: 10.1093.
    PubMed     Abstract available


    January 2021
  4. KHERA T, Du Y, Todt D, Deterding K, et al
    Long-lasting Imprint in the Soluble Inflammatory Milieu despite Early Treatment of Acute Symptomatic Hepatitis C.
    J Infect Dis. 2021 Jan 31. pii: 6124746. doi: 10.1093.
    PubMed     Abstract available


    November 2020
  5. JEYARAJAN AJ, Chung RT
    Insights Into the Pathophysiology of Liver Disease in HCV/HIV: Does it End With HCV Cure?
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  6. BAJIS S, Applegate TL, Grebely J, Matthews GV, et al
    Novel Hepatitic C Virus (HCV) Diagnosis and Treatment Delivery Systems: Facilitating HCV Elimination by Thinking Outside the Clinic.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  7. CHAPPELL CA, Jonas MM
    Hepatitis C Virus in Pregnancy: Are We Ready for Test and Treat?
    J Infect Dis. 2020;222.
    PubMed    


  8. THOMAS DL
    30 Years on the Road to Hepatitis C Elimination.
    J Infect Dis. 2020;222.
    PubMed    


  9. NAGGIE S, Wyles D
    Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection: Fulfilling the Potential on the Road to Elimination.
    J Infect Dis. 2020;222.
    PubMed    


  10. FALADE-NWULIA O, Sulkowski MS
    Hepatitis C Virus Treatment: Simplifying the Simple and Optimizing the Difficult.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  11. TROOSKIN SB, Dore G, Kostman J
    We Must Do Better: Addressing HCV Treatment Barriers in Persons Who Inject Drugs in the United States.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  12. ROCKSTROH JK, Boesecke C
    Hepatitis C Virus Treatment as Prevention: Challenges and Opportunities in Men Who Have Sex With Men.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  13. KAPPUS MR, Wolfe CR, Muir AJ
    Direct-Acting Antivirals and Organ Transplantation: Is There Anything We Can't Do?
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  14. HALEY DF, Edmonds A, Ramirez C, French AL, et al
    Direct-acting antiviral Hepatitis C treatment cascade and barriers to treatment initiation among US men and women with and without HIV.
    J Infect Dis. 2020 Nov 3. pii: 5952700. doi: 10.1093.
    PubMed     Abstract available


    October 2020
  15. VERGARA C, Valencia A, Thio CL, Goedert JJ, et al
    A multi-ancestry sex stratified genome-wide association study of spontaneous clearance of hepatitis C virus.
    J Infect Dis. 2020 Oct 29. pii: 5943036. doi: 10.1093.
    PubMed     Abstract available


  16. MESALAM AA
    Hepatitis C virus vaccine development: A step forward.
    J Infect Dis. 2020 Oct 11. pii: 5920711. doi: 10.1093.
    PubMed    


    September 2020
  17. JORDAN AE, Cleland CM, Wyka K, Schackman BR, et al
    Hepatitis C Virus Incidence in a Cohort in Medication-Assisted Treatment for Opioid Use Disorder in New York City.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  18. LEE AB, Karumberia S, Gilmore A, Williams E, et al
    Hepatitis C Among High-Risk Alabamians: Disease Burden and Screening Effectiveness.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  19. SHERBUK JE, Knick TK, Canan C, Ross P, et al
    Development of an Interdisciplinary Telehealth Model of Provider Training and Comprehensive Care for Hepatitis C and Opioid Use Disorder in a High-Burden Region.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  20. JORDAN AE, Cleland CM, Schackman BR, Wyka K, et al
    Hepatitis C Virus (HCV) Care Continuum Outcomes and HCV Community Viral Loads Among Patients in an Opioid Treatment Program.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  21. ASSOUMOU SA, Paniagua SM, Linas BP, Wang J, et al
    Rapid Versus Laboratory-Based Testing for HIV and Hepatitis C at a Drug Detoxification Treatment Center: A Randomized Trial.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  22. WESNER CA, Zhang W, Melstad S, Ruen E, et al
    Assessing County-Level Vulnerability for Opioid Overdose and Rapid Spread of Human Immunodeficiency Virus and Hepatitis C Infection in South Dakota.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  23. WINETSKY D, Burack D, Antoniou P, Garcia B, et al
    Psychosocial Factors and the Care Cascade for Hepatitis C Treatment Colocated at a Syringe Service Program.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  24. SPRINGER SA, Barocas JA, Wurcel A, Nijhawan A, et al
    Federal and State Action Needed to End the Infectious Complications of Illicit Drug Use in the United States: IDSA and HIVMA's Advocacy Agenda.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  25. ROWAN SE, Kamis KF, Beum R, Bryan K, et al
    Viral Hepatitis and Human Immunodeficiency Virus Testing and Linkage to Care for Individuals Enrolled in an Opioid Treatment Program.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


    August 2020
  26. CAPPY P, Lucas Q, Kankarafou N, Sureau C, et al
    No Evidence of HCV-Assisted HDV Propagation in a Large Cohort of Hepatitis C Positive Blood Donors.
    J Infect Dis. 2020 Aug 17. pii: 5893459. doi: 10.1093.
    PubMed     Abstract available


  27. WIJAYA RS, Read SA, Selvamani SP, Schibeci S, et al
    Hepatitis C virus eradication with interferon free, DAA-based therapy results in KLRG1+, hepatitis C virus-specific memory natural killer cells.
    J Infect Dis. 2020 Aug 10. pii: 5890638. doi: 10.1093.
    PubMed     Abstract available


    July 2020
  28. CATLETT B, Bajis S, Starr M, Dore GJ, et al
    Evaluation of the Aptima HCV Quant Dx Assay for HCV RNA detection from finger-stick capillary dried blood spot and venepuncture-collected samples.
    J Infect Dis. 2020 Jul 25. pii: 5876378. doi: 10.1093.
    PubMed     Abstract available


  29. VETTER BN, Reipold EI, Ongarello S, Audu R, et al
    Sensitivity and specificity of rapid diagnostic tests for hepatitis C virus with or without HIV coinfection: a multicentre laboratory evaluation study.
    J Infect Dis. 2020 Jul 2. pii: 5866494. doi: 10.1093.
    PubMed     Abstract available


    June 2020
  30. OGAWA E, Nomura H, Nakamuta M, Furusyo N, et al
    Development of Hepatocellular Carcinoma by Patients Aged 75-84 with Chronic Hepatitis C Treated with Direct-acting Antivirals.
    J Infect Dis. 2020 Jun 25. pii: 5862583. doi: 10.1093.
    PubMed     Abstract available


  31. KITABAYASHI J, Shirasaki T, Shimakami T, Nishiyama T, et al
    Upregulation of the Long Non-Coding RNA HULC by Hepatitis C Virus and its Regulation of Viral Replication.
    J Infect Dis. 2020 Jun 9. pii: 5854965. doi: 10.1093.
    PubMed     Abstract available


  32. NAGGIE S, Lusk S, Thompson JW, Mock M, et al
    Metabolomic signature as a predictor of liver disease events in patients with HIV/HCV co-infection.
    J Infect Dis. 2020 Jun 5. pii: 5851922. doi: 10.1093.
    PubMed     Abstract available


    May 2020
  33. ANTHONY DD, Sulkowski MS, Smeaton LM, Damjanovska S, et al
    HCV DAA Therapy in Persons with HIV-HCV Genotype 1 Coinfection Results in High Rate of Sustained Virologic Response and Heterogeneity in Normalization of Soluble Markers of Immune Activation.
    J Infect Dis. 2020 May 15. pii: 5836999. doi: 10.1093.
    PubMed     Abstract available


  34. DASGUPTA S, Imamura M, Gorstein E, Nakahara T, et al
    Modeling-based response-guided therapy for chronic hepatitis C under glecaprevir/pibrentasvir may identify patients for ultra-short treatment duration.
    J Infect Dis. 2020 May 4. pii: 5828592. doi: 10.1093.
    PubMed     Abstract available


    March 2020
  35. BALAGOPAL A, Smeaton LM, Quinn J, Venuto CS, et al
    Intrahepatic Viral Kinetics during Direct-Acting Antivirals for Hepatitis C in HIV Co-infection:The ACTG A5335S Substudy.
    J Infect Dis. 2020 Mar 23. pii: 5810960. doi: 10.1093.
    PubMed     Abstract available


  36. SUN B, Abadjian L, Monto A, Freasier H, et al
    HCV cure in HIV coinfection dampens inflammation and improves cognition through multiple mechanisms.
    J Infect Dis. 2020 Mar 11. pii: 5802775. doi: 10.1093.
    PubMed     Abstract available


  37. AKIYAMA MJ, Lipsey D, Ganova-Raeva L, Punkova L, et al
    A Phylogenetic Analysis of HCV Transmission, Relapse, and Reinfection Among People Who Inject Drugs Receiving Opioid Agonist Therapy.
    J Infect Dis. 2020 Mar 9. pii: 5801905. doi: 10.1093.
    PubMed     Abstract available


    February 2020
  38. OLBRICH A, Wardemann H, Bohm S, Rother K, et al
    Erratum to: Repertoire and Neutralizing Activity of Antibodies Against Hepatitis C Virus E2 Peptide in Patients With Spontaneous Resolution of Hepatitis C.
    J Infect Dis. 2020 Feb 15. pii: 5736576. doi: 10.1093.
    PubMed    


    January 2020
  39. LINAS BP
    Time for a New Approach to Guidance for HIV and HCV Testing Among Persons Who Inject Drugs.
    J Infect Dis. 2020 Jan 30. pii: 5718241. doi: 10.1093.
    PubMed    


  40. BULL-OTTERSON L, Huang YA, Zhu W, King H, et al
    HIV and Hepatitis C Virus Infection Testing Among Commercially Insured Persons Who Inject Drugs, United States, 2010-2017.
    J Infect Dis. 2020 Jan 30. pii: 5718242. doi: 10.1093.
    PubMed     Abstract available


  41. GREBELY J, Catlett B, Jayasinghe I, Valerio H, et al
    Time to detection of hepatitis C virus infection with the Xpert HCV Viral Load Fingerstick Point-of-Care Assay: Facilitating a more rapid time to diagnosis.
    J Infect Dis. 2020 Jan 29. pii: 5717213. doi: 10.1093.
    PubMed     Abstract available


  42. CLIPMAN SJ, Duggal P, Srikrishnan AK, Saravanan S, et al
    Prevalence and phylogenetic characterization of hepatitis C among men who have sex with men in India: limited evidence for sexual transmission.
    J Infect Dis. 2020 Jan 9. pii: 5699640. doi: 10.1093.
    PubMed     Abstract available


    November 2019
  43. KOVACS AAZ, Kono N, Wang CH, Wang D, et al
    Association of HLA Genotype With T-Cell Activation in Human Immunodeficiency Virus (HIV) and HIV/Hepatitis C Virus-Coinfected Women.
    J Infect Dis. 2019 Nov 10. pii: 5618844. doi: 10.1093.
    PubMed     Abstract available


    September 2019
  44. ZOU B, Yeo YH, Le MH, Henry L, et al
    Prevalence of viremic HCV infection by age, race/ethnicity, birthplace and disease awareness among viremic persons in the U.S., 1999-2016.
    J Infect Dis. 2019 Sep 27. pii: 5575100. doi: 10.1093.
    PubMed     Abstract available


    August 2019
  45. KOSLOSKI MP, Oberoi R, Wang S, Viani RM, et al
    Drug-Drug Interactions of Glecaprevir and Pibrentasvir Coadministered with Human Immunodeficiency Virus Antiretrovirals.
    J Infect Dis. 2019 Aug 29. pii: 5556482. doi: 10.1093.
    PubMed     Abstract available


    March 2019
  46. KUSEJKO K, Bachmann N, Chaudron SE, Nguyen H, et al
    A systematic phylogenetic approach to study the interaction of HIV-1 with coinfections, non-communicable and opportunistic diseases.
    J Infect Dis. 2019 Mar 4. pii: 5369724. doi: 10.1093.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: